Scholarlink

Purpose <p>To compare the diagnostic performance of [<sup>18</sup>F]FDG and [<sup>18</sup>F]PSMA‑1007 PET/CT for detecting primary tumors, regional lymph node involvement, and distant metastases in recently diagnosed muscle‑invasive bladder cancer (MIBC).</p> Methods <p>Prospective single‑center cohort of six patients (ages 57–82). Both PET/CTs were acquired within 30&#xa0;days under EANM/SNMMI-conformant protocols, with blinded consensus readings and post-diuretic pelvic acquisitions.</p> Results <p>[<sup>18</sup>F]PSMA‑1007 identified 15 lesions versus 14 with [<sup>18</sup>F]FDG. Primary bladder lesions were detected in 5 of 6 patients, compared to 3 of 6 patients. Both tracers detected nodal metastases in three patients and bone metastases in one. An [<sup>18</sup>F]FDG‑avid pulmonary lesion near the spleen was not detected with [<sup>18</sup>F]PSMA‑1007 owing to physiological splenic uptake.</p> Conclusion <p>Both tracers showed comparable sensitivity for metastatic disease. The hepatobiliary clearance of [<sup>18</sup>F]PSMA‑1007 improved visualization of intravesical disease, supporting its use in staging and potential theranostic strategies in selected MIBC patients. Such real-world findings inform refinements for future study procedures, logistics, and methodological design, which are essential for minimizing research waste by identifying potential problems early.</p> <p>Trial Registration: Not applicable.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparison of [18F]FDG and [18F]PSMA-1007 PET/CT in the Evaluation of Muscle-Invasive Bladder Cancer: A Pilot Feasibility Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月23日

查看全文
  • Natália Dalsenter Avilez,
  • Ricardo N. Tineo,
  • Juliano Tomé Rodrigues,
  • Arthur Degani Ottaiano,
  • Helena P. A. Saito,
  • Bárbara Juarez Amorim,
  • José Barreto Campello Carvalheira,
  • Leonardo O. Reis,
  • Celso Dario Ramos

摘要

Purpose

To compare the diagnostic performance of [18F]FDG and [18F]PSMA‑1007 PET/CT for detecting primary tumors, regional lymph node involvement, and distant metastases in recently diagnosed muscle‑invasive bladder cancer (MIBC).

Methods

Prospective single‑center cohort of six patients (ages 57–82). Both PET/CTs were acquired within 30 days under EANM/SNMMI-conformant protocols, with blinded consensus readings and post-diuretic pelvic acquisitions.

Results

[18F]PSMA‑1007 identified 15 lesions versus 14 with [18F]FDG. Primary bladder lesions were detected in 5 of 6 patients, compared to 3 of 6 patients. Both tracers detected nodal metastases in three patients and bone metastases in one. An [18F]FDG‑avid pulmonary lesion near the spleen was not detected with [18F]PSMA‑1007 owing to physiological splenic uptake.

Conclusion

Both tracers showed comparable sensitivity for metastatic disease. The hepatobiliary clearance of [18F]PSMA‑1007 improved visualization of intravesical disease, supporting its use in staging and potential theranostic strategies in selected MIBC patients. Such real-world findings inform refinements for future study procedures, logistics, and methodological design, which are essential for minimizing research waste by identifying potential problems early.

Trial Registration: Not applicable.

Graphical Abstract